ticagrelor + prasugrel

Ticagrelor + prasugrel is a combination of two oral antiplatelet agents, both of which are P2Y12 receptor antagonists. Ticagrelor is a cyclopentyltriazolopyrimidine that binds reversibly to the platelet P2Y12 ADP receptor, inhibiting ADP-mediated platelet activation and aggregation. Prasugrel is a thienopyridine prodrug that irreversibly inhibits the same receptor after metabolic activation. Both drugs are used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndromes (ACS), particularly those undergoing percutaneous coronary intervention (PCI). While each drug alone has demonstrated efficacy in preventing myocardial infarction and stroke, their combined use as dual P2Y12 inhibition increases bleeding risk compared to monotherapy and is not standard clinical practice; such combinations have been studied primarily for research purposes or in specific high-risk scenarios[4][5][6].

Other names

ticagrelor + prasugrel